A previous study has shown that the dihydrofolate reductase (DHFR) inhibitor methotrexate (MTX) initiates p53-dependent apoptosis and restores E-cadherin expression by downregulating HDAC/EZH2, which subsequently curtails NSCLC progression [46]. This evidence concerns the gene EZH2 and non-small cell lung carcinoma.